PAKIANATHAN DEEPIKA 4

What Happened

• Deepika Pakianathan, a director of Mereo BioPharma Group plc (MREO), received a derivative award of 66,000 ordinary shares on February 26, 2026. The grant price is $0.00 (an award/compensation grant), so no cash was paid.
• The filing identifies this as transaction type "A" (award/grant). The award vests in substantially equal monthly installments over one year beginning on the grant date.

Key Details

• Transaction date: 2026-02-26; Filing date: 2026-02-27 (timely).
• Shares granted: 66,000 ordinary shares; reported acquisition price: $0.00 (derivative award).
• Vesting: Substantially equal monthly installments over one year from Feb 26, 2026 (Footnote F1).
• ADS note: Each American Depositary Share (ADS) represents five ordinary shares (Footnote F2). If converted, 66,000 ordinary shares = 13,200 ADS.
• Shares owned after the transaction: Not specified in the provided filing details.
• Transaction code: A = Award/Grant (not an open-market purchase or sale).

Context

• This was a compensation award, not a cash purchase or a sale. Such grants are commonly used for compensation and retention and generally vest over time, aligning the recipient’s interests with the company’s future performance.
• Because the award is derivative, the recipient may not receive freely tradable shares until vesting conditions are met. This filing alone does not indicate an insider belief about the company's near-term stock direction.